From: COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center
Model
PR
95% CI
P-value
Crude (unadjusted)
1.02
0.90 to 1.16
0.75
Model 1: crude + demographic characteristics*
0.89 to 1.16
0.79
Model 2: model 1 + clinical characteristics**
1.01
0.84